Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients

• 小森, 宏之

• 別府, 透

• 馬場, 祥史

• 堀野, 敬

• 増田, 稔郎

• 林, 洋光

• 岡部, 弘尚

• 太田尾, 龍

• 渡邊, 雅之

• 高森, 啓史

• 猪山, 賢一

• 馬場, 秀夫

• Beppu, Toru

• Horino, Kei

• Imsung, Choi

• Okabe, Hirohisa

• Ootao, Ryuu

• Iyama, Kenichi

• Baba, Hideo

抄録

application/pdf

application/pdf

論文(Article)

Background This study was performed to clarify the influence of preoperative chemotherapy on liver function and the correlation between histological hepatic injury and the postoperative outcome in patients with colorectal liver metastases who underwent a hepatic resection. Methods Twenty-seven patients who underwent a hepatic resection for colorectal liver metastases were included. Fifteen patients with initially unresectable colorectal liver metastases who were able to undergo a tumor resection after FOLFOX (oxaliplatin plus fluorouracil and leucovorin, with a mean number of 7.7 cycles) were compared to 12 patients who underwent a hepatectomy with no preoperative chemotherapy. The postoperative mortality, morbidity, changes in liver function tests, and pathology of the resected liver were examined. Results Preoperative FOLFOX therapy was significantly associated with the macroscopic appearance of oxaliplatinassociated blue liver (p = 0.02), and a tendency toward sinusoidal dilatation (33.3% in the FOLFOX group versus 8.3% in the no-chemotherapy group, p = 0.056). Preoperative liver function tests showed that the albumin and indocyanine green retention rate at 15 min (ICG-R15) test values were significantly worse after FOLFOX therapy; however, intraoperative events, postoperative liver function test values, and morbidity rates were similar in the two groups. There was no postoperative mortality in any of the patients. Conclusions Although preoperative FOLFOX administration in patients with colorectal liver metastases caused macroscopic blue liver, microscopic sinusoidal dilatationin the liver parenchyma, and a significant decrease in liver function, there was no increase in the morbidity and mortality rates, in comparison to findings in patients without preoperative chemotherapy.

http://www.springerlink.com/content/pnr82711x3652312/

収録刊行物

• International Journal of Clinical Oncology

  International Journal of Clinical Oncology 15 (3), 263-270, 2010-06

  Japan Society of Clinical Oncology

キーワード

• Colorectal liver metastases
• Fluorouracil and leucovorin (FOLFOX)
• Hepatic resection
• Oxaliplatin
• Postoperative morbidity
• Sinusoidal dilatation

詳細情報

• CRID: 1050845762858786816
• NII論文ID: 10027202558
• NII書誌ID: AA11086579
• HANDLE: 2298/19861
• Web Site: https://kumadai.repo.nii.ac.jp/records/24847
• Web Site: https://search.jamas.or.jp/link/ui/2011052844
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles